OncoMatch/Clinical Trials/NCT06050694
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
Is NCT06050694 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies glofitamab for diffuse large b cell lymphoma (dlbcl).
Treatment: glofitamab — This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline
Prior exposure to any anthracycline
Cannot have received: anti-CD20 antibody (rituximab)
Prior exposure to...rituximab
Cannot have received: CD3-targeted bispecific antibody
Prior exposure to...cluster of differentiation 3 (CD3) targeted bispecific antibody
Lab requirements
Blood counts
Absolute Neutrophil Count (ANC) <1.0 x10^9/L (subjects with bone marrow involvement by lymphoma are eligible regardless of ANC); Hemoglobin (Hgb) ≤ 9 g/dL; Platelets <50 x10^9/L (subjects with bone marrow involvement by lymphoma are eligible regardless of platelet count)
Kidney function
Creatinine clearance <30 mL/min
Liver function
Total serum bilirubin >2 times the upper limit of normal (or <3 times for Gilbert's disease or documented hepatic involvement by lymphoma), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >3 times the upper limit of normal (or >5 times for documented hepatic involvement by lymphoma)
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%, as determined on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) ≥ 50%... Absolute Neutrophil Count (ANC) <1.0 x10^9/L... Hemoglobin (Hgb) ≤ 9 g/dL... Platelets <50 x10^9/L... Total serum bilirubin >2 times the upper limit of normal (or <3 times for Gilbert's disease or documented hepatic involvement by lymphoma), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >3 times the upper limit of normal (or >5 times for documented hepatic involvement by lymphoma)... Creatinine clearance <30 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify